Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Multiple Myeloma 70Leukemia, Lymphocytic, Chronic, B-Cell 26Lymphoma, Mantle-Cell 15Lymphoma, Follicular 15Lymphoma, Large B-Cell, Diffuse 14Leukemia, Myeloid, Acute 14Lymphoma, B-Cell, Marginal Zone 13Lymphoma, Non-Hodgkin 12Recurrence 11Neoplasms, Plasma Cell 10Lymphoma 10Myelodysplastic Syndromes 9Hodgkin Disease 8Neoplasms 7Leukemia 7Burkitt Lymphoma 7Waldenstrom Macroglobulinemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, T-Cell, Cutaneous 6Lymphoma, B-Cell 6Sezary Syndrome 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Mycosis Fungoides 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Large-Cell, Immunoblastic 4Astrocytoma 4Smoldering Multiple Myeloma 3Prostatic Neoplasms 3Oligodendroglioma 3Melanoma 3

Interventions

pembrolizumab 11Nivolumab 7Sunitinib 6Cyclophosphamide 6aldesleukin 5Sorafenib 5Everolimus 5temsirolimus 4belzutifan 4atezolizumab 4Ipilimumab 4fludarabine 3cabozantinib 3Interferon-alpha 3Gene Expression Profiling 3Fluorouracil 3Docetaxel 3Cetuximab 3Busulfan 3valspodar 2sargramostim 2perifosine 2pazopanib 2ixabepilone 2entinostat 2ciforadenant 2belinostat 2Thiotepa 2Temozolomide 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Kidney Neoplasms × Lenalidomide × Clear all
NCT01218555 2022-01-27

Study of Everolimus (RAD001) in Combination With Lenalidomide

Emory University

Phase 1 Completed
44 enrolled 9 charts
EndocrineGenitourinaryNET

Kidney Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡